LA
Lilly Asia Ventures
Lilly Asia Ventures is a Series A to Series C stage investment firm. It has made 21 investments. 35% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 2 prior). Average disclosed round size is $73.7M (across 24 rounds with reported amounts).
Portfolio
21
Fund Size
—
Top Stage
Series B
Last 12 Mo
1
Team
FC
Fei Chen
Managing Partner
TY
Tao Yu
Managing Director
JZ
Jieyu Zou
Partner
DK
Dezhi Kang
Vice President
HX
Hansen Xu
Vice President
JL
Judith Li
Investment Professional
LW
Lilian Wan
Investment Professional
S(
Stacie (Zongxi) Li
Life Sciences Investment
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
31 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Avenzo | Series B | $60M | Sep 2025 |
| UUnited InnoMed | Unknown | $20M | Apr 2025 |
| Avenzo | Unknown | $386M | Nov 2024 |
| LLynk Pharmaceuticals | Unknown | — | Sep 2023 |
 Pyrotech | Series A | — | Jul 2023 |
| LLynk Pharmaceuticals | Unknown | $50M | Aug 2021 |
 Elpiscience | Series C | $105M | May 2021 |
| 和和誉生物 | Series D | $123M | Jan 2021 |
| LLynk Pharmaceuticals | Series B | $50M | Jan 2021 |
| GGracell | Series C | $100M | Oct 2020 |
| DdMed Biopharmaceutical | Series B | $50M | Oct 2019 |
 Peijia Medical | Ipo | $100M | Jan 2019 |
 Ionova | Series A | $17M | Jan 2019 |
| DdMed Biopharmaceutical | Series B | $50M | Jan 2019 |
| Elpiscience | Series A | $20M | Dec 2018 |
| TTmunity | Series A | — | Apr 2018 |
| CCarsgen Therapeutics | Series C | $186M | Jan 2018 |
| Peijia Medical | Series B | — | Jan 2018 |
 Turning Point Therapeutics, Inc. | Series C | $45M | May 2017 |
| TTmunity | Unknown | $10M | Jan 2016 |
 JUST Biotherapeutics | Unknown | $15M | Jan 2016 |
| JUST Biotherapeutics | Series A | $15M | Jan 2015 |
| LLupeng Pharmaceutica | Unknown | $35M | — |
| JJieti Medical | Strategic | — | — |
 Singleron Biotechnologies | Series A | $10M | — |
Page 1 of 2
Top Co-Investors
LAV7 shared
OrbiMed5 shared
Pivotal Life Sciences4 shared
Vivo Capital4 shared
Legend Capital4 shared
ARCH Venture Partners4 shared
CDH Investments4 shared
Rock Springs Capital4 shared
Lake Bleu Capital3 shared
SR One3 shared
Longwood Fund3 shared
Foresite Capital3 shared
Med-Fine Capital2 shared
Cormorant Asset Management2 shared
Nextech Invest Ltd.2 shared
Matrix Partners China2 shared
Hillhouse Capital2 shared
Dyee Capital2 shared
Andreessen Horowitz2 shared
Last updated: 8 September 2026